Zhejiang Hisun Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Zhejiang Hisun Pharmaceutical Co., Ltd. carries a market capitalization of 12.92B, placing it among publicly traded companies globally. Its enterprise value stands at 12.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.92B |
| Enterprise Value | 12.94B |
Share Statistics
Zhejiang Hisun Pharmaceutical Co., Ltd. currently has 1.20B shares outstanding.
| Shares Outstanding | 1.20B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Zhejiang Hisun Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 22.73. The price-to-sales ratio is 1.02, and the price-to-book ratio stands at 2.79.
| PE Ratio | 22.73 |
| PS Ratio | 1.02 |
| PB Ratio | 2.79 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | 37.12 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Zhejiang Hisun Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 10.77 and an EV/FCF ratio of 34.60. The EV/Sales ratio of 1.25 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.77 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.25 |
| EV / EBITDA | 10.77 |
| EV / EBIT | 10.77 |
| EV / FCF | 34.60 |
Financial Position
Zhejiang Hisun Pharmaceutical Co., Ltd. maintains a current ratio of 0.91, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.84, indicating elevated leverage, while an interest coverage ratio of 9.76 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 0.91 |
| Quick Ratio | 0.29 |
| Debt / Equity | 45.84 |
| Debt / EBITDA | 3.28 |
| Interest Coverage | 9.76 |
Financial Efficiency
Zhejiang Hisun Pharmaceutical Co., Ltd. posts a return on equity of 12.54 and a return on invested capital of 6.76.
| Return on Equity (ROE) | 12.54 |
| Return on Assets (ROA) | 2.86 |
| Return on Invested Capital (ROIC) | 6.76 |
| Return on Capital Employed (ROCE) | 6.68 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.38 |
Taxes
Over the trailing twelve months, Zhejiang Hisun Pharmaceutical Co., Ltd. has paid 174.61M in income taxes, reflecting an effective tax rate of 27.42.
| Income Tax | 174.61M |
| Effective Tax Rate | 27.42 |
Stock Price Statistics
Zhejiang Hisun Pharmaceutical Co., Ltd.'s stock has gained approximately 1.86047% over the past 52 weeks. The 50-day moving average sits at 10.57, while the 200-day moving average is 10.52.
| Beta (5Y) | N/A |
| 52-Week Price Change | 1.86047% |
| 50-Day Moving Average | 10.57 |
| 200-Day Moving Average | 10.52 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zhejiang Hisun Pharmaceutical Co., Ltd. generated 10.35B in revenue and converted that into 465.01M in net income, yielding earnings per share of 0.40. EBITDA reached 1.20B, while operating income came in at 1.20B.
| Revenue | 10.35B |
| Gross Profit | 4.63B |
| Operating Income | 1.20B |
| Pretax Income | 636.81M |
| Net Income | 465.01M |
| EBITDA | 1.20B |
| EBIT | 1.20B |
| Earnings Per Share (EPS) | 0.40 |
Balance Sheet
Zhejiang Hisun Pharmaceutical Co., Ltd. holds 1.81B in cash and equivalents against 3.94B in total debt, resulting in a net debt position of 927.89M. Total book value stands at 3.79B, with working capital of -545.33M providing operational flexibility.
| Cash & Cash Equivalents | 1.81B |
| Total Debt | 3.94B |
| Net Debt | 927.89M |
| Equity (Book Value) | 3.79B |
| Book Value Per Share | 3.32 |
| Working Capital | -545.33M |
Cash Flow
After subtracting -284.72M in capital expenditures, free cash flow totaled -284.72M - equivalent to -0.25 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -284.72M |
| Free Cash Flow | -284.72M |
| FCF Per Share | -0.25 |
Margins
Zhejiang Hisun Pharmaceutical Co., Ltd. operates with a gross margin of 44.77, reflecting its pricing power and cost economics. The operating margin of 11.62 and net profit margin of 4.49 provide insight into operational efficiency.
| Gross Margin | 44.77 |
| Operating Margin | 11.62 |
| Pretax Margin | 6.15 |
| Profit Margin | 4.49 |
| EBITDA Margin | 11.62 |
Dividends & Yields
The company's payout ratio of 80.89 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.33 |
| Dividend Yield | N/A |
| Payout Ratio | 80.89 |
| Shareholder Yield | 17.09 |
| FCF Yield | 2.69 |
Stock Splits
Zhejiang Hisun Pharmaceutical Co., Ltd.'s most recent stock split took place on May 25, 2012 with a 5:8 split ratio.
| Last Split Date | 5/25/2012 |
| Split Ratio | 5:8 |
Scores
Zhejiang Hisun Pharmaceutical Co., Ltd. posts an Altman Z-Score of 2.09, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.09 |